Brave Asset Management’s Allergan plc AGN Stock Holding History

Brave Asset Management’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,795	Closed	-$301K	–	168
2019 Q2	$301K	Hold	1,795	–	–	0.17%	89
2019 Q1	$263K	Hold	1,795	–	–	0.15%	105
2018 Q4	$240K	Hold	1,795	–	–	0.16%	101
2018 Q3	$342K	Sell	1,795 -131	-7%	-$24.1K	0.18%	89
2018 Q2	$321K	Sell	1,926 -3,495	-64%	-$561K	0.19%	93
2018 Q1	$912K	Buy	5,421 +1,058	+24%	+$177K	0.55%	57
2017 Q4	$714K	Sell	4,363 -2,488	-36%	-$446K	0.37%	69
2017 Q3	$1.4M	Buy	6,851 +1,409	+26%	+$328K	0.74%	45
2017 Q2	$1.32M	Buy	5,442 +2,271	+72%	+$534K	0.7%	44
2017 Q1	$758K	Buy	3,171 +1,125	+55%	+$262K	0.44%	62
2016 Q4	$430K	Buy	2,046 +1,876	+1,104%	+$389K	0.28%	89
2016 Q3	$39K	Hold	170	–	–	0.03%	241
2016 Q2	$39K	Hold	170	–	–	0.03%	237
2016 Q1	$46K	Hold	170	–	–	0.03%	221
2015 Q4	$53K	Hold	170	–	–	0.04%	215
2015 Q3	$46K	Hold	170	–	–	0.04%	216
2015 Q2	$52K	Hold	170	–	–	0.04%	228
2015 Q1	$51K	Buy	+170	New	+$48.5K	0.04%	222

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brave Asset Management's AGN Position: Q3 2019 in Review

Brave Asset Management sold out of Allergan plc (AGN) in Q3 2019, closing a stake of 1,795 shares — an estimated $301K sold.

Brave Asset Management first reported a position in AGN in Q1 2015 and held it in 18 quarters. The position peaked at $1.4M in Q3 2017. 921 funds tracked by Wall St. Rank hold AGN as of Q3 2019.

Brave Asset Management reported no remaining Allergan plc position as of Q3 2019 after selling out during the quarter.
Brave Asset Management sold 1,795 Allergan plc shares in Q3 2019, an estimated $301K.
Brave Asset Management first reported a position in Allergan plc in Q1 2015 and held it in 18 quarters.
Brave Asset Management's Allergan plc position peaked at $1.4M in Q3 2017.
921 funds tracked by Wall St. Rank held Allergan plc as of Q3 2019.

Based on Brave Asset Management's 13F filing for Q3 2019, filed 24 Oct 2019.